Influenza Vaccination Strategy for Patients With Hematologic Malignancy
Eligible age
19+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population
Sponsor: Asan Medical Center
You may qualify if…
- ✓ Adults aged 19 years or older
- ✓ Confirmed diagnosis of hematologic malignancy, including:
- ✓ non-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders
You may not qualify if…
- ✕ Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)
- ✕ Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures
- ✕ Known hypersensitivity to influenza vaccine components
- ✕ Influenza vaccination within the preceding 6 months
- ✕ Any other condition deemed clinically inappropriate for study participation at investigator discretion
Source: ClinicalTrials.gov · NCT07485855 · last updated 2026-09-01